• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Thailand’s Prince Mahidol Award honours Dr Bernard Pécoul, Founder of DNDi, for his service to public health

DNDi’s Executive Director joins a prestigious list of figures recognized for their contributions in fields of medicine and global health

Home > Press releases

Thailand’s Prince Mahidol Award honours Dr Bernard Pécoul, Founder of DNDi, for his service to public health

DNDi’s Executive Director joins a prestigious list of figures recognized for their contributions in fields of medicine and global health

Dr Bernard Pécoul
Bangkok/Kuala Lumpur — 12 Nov 2020
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • ไทย
    • 中文
    • اللغة العربية
    • Español
    • Português
    • 日本語

Dr Bernard Pécoul, Founder and Executive Director of the international not-for-profit medical research organization, Drugs for Neglected Diseases initiative (DNDi), has received Thailand’s Prince Mahidol Award 2020 for his contribution to furthering research for neglected diseases around the world.

The Prince Mahidol Award Foundation honours health and science leaders each year for their outstanding achievements in the fields of medicine and global public health. Former laureates include Dr Anthony Fauci (United States), Prof. Barry J. Marshall (Australia), Prof. Harald zur Hausen (Germany), Dr Satoshi Omura (Japan), and Prof. Tu Youyou (China).

‘It is an immense honour to join the list of health laureates of the Prince Mahidol Award,’ said Dr Pécoul. ‘This award also holds a special significance for me because I began my career in Thailand, where I was working in refugee camps 35 years ago. It was there that I saw first-hand the medical neglect that eventually led me and many partners to create DNDi.’

Dr Bernard Pécoul has led DNDi since its formation in 2003. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, it dedicated a portion of its prize award to exploring an innovative, alternative, not-for-profit model for developing drugs for hundreds of millions of neglected patients worldwide. DNDi was born. Its founding partners included MSF, the World Health Organization (WHO), and a group of five international public health institutions – the Malaysian Ministry of Health among them.

From left to right: Professor Supat Vanichakarn, M.D. Secretary-General of the Prince Mahidol Award Foundation under the Royal Patronage; Professor Dr Prasit Watanapa, M.D., Ph.D. Dean of Faculty of Medicine Siriraj Hospital, Mahidol University; Professor Vicharn Panich, M.D. Chairman of the International Award Committee of the Prince Mahidol Award Foundation; Mr. Tanee Sangrat, Director-General of the Department of Information, Ministry of Foreign Affairs, and Chairman of the Sub-Committee on Public Relations of the Prince Mahidol Award Foundation; Dr John R. MacArthur Regional Director, Southeast Asia (SEAS) Regional Office, US Centers for Disease Control and Prevention; Dr Taraneh Shojaei Regional Counsellor in Global Health, South-East Asia, at the French Embassy

‘The Prince Mahidol award is a well-deserved recognition of Dr Pécoul’s unwavering commitment to treating all people’s health as a matter of priority, no matter whether they are rich or poor,’ said Tan Sri Dr Noor Hisham Abdullah, Malaysian Director General of Health and DNDi Board Member. ‘An excellent example of that commitment bearing fruit is our close collaboration in Malaysia, where DNDi and the Ministry of Health are making tremendous progress expanding access to affordable treatment for people living with hepatitis C.’

Under Dr Pécoul’s leadership, DNDi has delivered eight new treatments for leishmaniasis, sleeping sickness, and Chagas disease – some of the world’s most neglected diseases – as well as for malaria and for children living with HIV. Working in partnership with hundreds of public and private actors around the world, the organization has developed a robust portfolio of projects spanning drug discovery, clinical research, and treatment access for these diseases, as well as for river blindness, mycetoma, and hepatitis C. Together with WHO, DNDi also launched the Global Antibiotic Research and Development Partnership (GARDP) in 2016, now an independent not-for-profit organization developing new treatments to fight drug-resistant infections that pose the greatest threat to health.

Dr Pécoul has devoted much of his career to advocating for access to medicines and creating an alternative R&D model driven exclusively by patients’ medical needs, not profits. He started his career in 1983 as a doctor with MSF, carrying out field missions in Africa, Latin America, and Asia. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specializing in epidemiology. He became General Director of MSF France in 1991 and then served as Founding Director of the MSF Campaign for Access to Essential Medicines from 1998 to 2003.

‘Dr Pécoul firmly believes that low and middle-income countries can successfully build their own solutions to their own health problems, especially through the power of partnership and collaboration,’ said Jean-Michel Piedagnel, Director of DNDi’s South-East Asia Regional Office, based in Malaysia. ‘This award serves as a recognition of DNDi’s strong footprint in Thailand and South-East Asia, and we are certain it will contribute to support our work and strengthen our vital partnerships tackling hepatitis C, antimicrobial resistance, dengue fever, and other major public health challenges facing our region.’

Because of the current pandemic, this year’s laureates will be formally invited to attend the award ceremony in Thailand in 2022. The laureates will be invited soon to deliver online lectures about their achievements.

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit R&D organization working to deliver new treatments for neglected patients, in particular for sleeping sickness, Chagas disease, leishmaniasis, river blindness, mycetoma, HIV, and hepatitis C virus. DNDi’s ambition is to help enable widespread access to HCV treatment through the development and registration of affordable, safe, and efficacious pan-genotypic direct-acting antivirals (DAAs), and through advocacy for the policy change and political will needed to remove barriers to access to DAAs globally.

About the Prince Mahidol Award Foundation:

The Prince Mahidol Award Foundation was established by the permission of His Majesty the King Bhumibol Adulyadej, in accordance with the proposal of Faculty of Medicine, Siriraj Hospital, in commemoration of the Centenary Birthday Anniversary of His Royal Highness Prince Mahidol of Songkla on 1 January 1992. The Foundation was established in honour of His Royal Highness and in recognition of his exemplary contribution as “The Father of Modern Medicine and Public Health of Thailand.”

Media contacts

DNDi South-East Asia regional office
Molly Jagpal
Mobile: +60 (0)12 546 8362
Email: mjagpal@dndi.org  

DNDi Geneva office
Frederic Ojardias
Email: fojardias@dndi.org

Photo credit: FBBVA, Prince Mahidol Foundation

Asia Thailand

Read, watch, share

Loading...
Patient with healthcare worker in hospital
Press releases
30 Mar 2023

Eumycetoma: DNDi welcomes Japan’s GHIT Fund support for registration of new treatment for deeply neglected fungal disease

Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo